{"id":28484,"date":"2023-08-17T15:14:23","date_gmt":"2023-08-17T14:14:23","guid":{"rendered":"https:\/\/cannabishealthnews.co.uk\/?p=28484"},"modified":"2023-08-18T16:28:32","modified_gmt":"2023-08-18T15:28:32","slug":"nhs-scotland-to-fund-clinical-trial-on-cbd-and-endometriosis","status":"publish","type":"post","link":"https:\/\/cannabishealthnews.co.uk\/2023\/08\/17\/nhs-scotland-to-fund-clinical-trial-on-cbd-and-endometriosis\/","title":{"rendered":"NHS Scotland to fund clinical trial on CBD and endometriosis"},"content":{"rendered":"
The <\/span>Chief Scientist Office, part of the Scottish Government Health Directorate responsible for funding research in NHS Scotland, will provide \u00a3300,000 for the trial, <\/span>Ananda Developments, announced in a press release<\/a> on Tuesday 15 August.\u00a0\u00a0<\/span><\/p>\r\n Endometriosis, a condition where cells similar to the womb-lining are found elsewhere in the body, affects around 190 million women worldwide and often leads to debilitating pelvic pain among other symptoms.\u00a0<\/span><\/p>\r\n The placebo-controlled randomised control trial (RCT), <\/span>led by Dr Lucy H R Whitaker, a clinical lecturer in Obstetrics and Gynaecology at The University of Edinburgh, <\/span>will look at the effects of Ananda\u2019s oral CBD tincture (MRX1) in 100 women with pelvic pain related to endometriosis.<\/span><\/p>\r\n MRX1 is a broad-spectrum oral tincture containing CBD isolate and additional terpenes.The company is said to have developed a proprietary method for formulating cannabis medicines which are essentially THC-free but contain other components of cannabis which contribute to the<\/span> \u2018entourage effect\u2019.\u00a0<\/span><\/a><\/p>\r\n